It was announced today thatVicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel...
Joint press release; UC Berkeley and Novartis Institutes for BioMedical Research
Illustration of DUBTAC in action against a target. (Courtesy Nomura Lab)
Novartis-Berkeley Translational Chemical Biology Institute combines Novartis expertise in chemical biology and medicinal chemistry with Berkeley’s expertise in covalent chemoproteomics and chemistry methodologies Research collaboration aims to unlock...
Scientists have found that cancers in the pancreas (left) readily metastasize because these tumors suppress levels of an enzyme, MSRA, that pulls oxygen atoms off amino acids called methionine. As MSRA levels decrease, methionines on...
Becky Bish | The Mark Foundation for Cancer Research
Nomura in his lab at UC Berkeley. Photo: Elena Zhukova
Throughout the grim reality of a global pandemic that has disrupted normal life for months, one persistent bright spot has been the robust response of the biomedical research community. The battle to develop vaccines and drugs to fight the SARS-CoV-2 virus and COVID-19, the disease which it causes,...
A colored scanning electron micrograph of a cell of a common type of lung cancer, called non-small cell cancer. A new drug targets the mutated protein that leads to uncontrolled growth. Credit Steve Gschmeissner/Science Source
After 40 years of effort, researchers have finally succeeded in switching off...
The DNA-cutting proteins central to CRISPR-Cas9 and related gene-editing tools originally came from bacteria, but a newfound variety of Cas proteins apparently evolved in viruses that infect bacteria. The new Cas proteins were found in the largest known bacteria-infecting viruses, called bacteriophages, and are the most compact working Cas variants yet discovered — half the size of today’s workhorse, Cas9.
Researchers in the UC Berkeley lab of John Kuriyan, Chancellor's Professor at the University of California, Berkeley in the departments of Molecular and Cell Biology and Chemistry, have utilized powerful NSF funded supercomputers at the University of Texas Advanced Computing Center and the Pittsburgh Supercomputing Center to uncover the mechanism that activates cell mutations found in about 50 percent of melanomas.
Even the hippest chemist doesn’t know how many potentially world-changing chemistry start-ups are out there. As we at C&EN present our fifth class of 10 Start-Ups to Watch (two companies are founded by UC Berkeley faculty and alum), we can confirm that there are definitely hundreds, and perhaps thousands. That makes the job of picking just 10 a challenge—though an inspiring one. This year’s choices were selected after vigorous debate by our writers and editors. We made our own lists based on our day-to-day reporting and scoured the hundreds of firms nominated by readers and advisers from around the world. We picked winners for their groundbreaking chemistry as well as the importance of the problems they are tackling.
When Chu-Moyer was tapped to head up the research and chemistry groups across Amgen’s three U.S. R&D sites in 2014, she knew she would have to make some changes for the company to succeed in bringing a KRAS inhibitor into clinical trials, along with other novel treatments for cancer, cardiovascular disease and neurological disorders. For one, she needed to improve the collaboration between scientists who had different areas of expertise—and who lived and worked in different zip codes.
